Cyclosporine

Molecular mechanism of action

The pharmacodynamics of the drug represents a complex and strictly sequential intracellular cascade that unfolds directly inside immune cells. The initial stage of the mechanism of action starts the moment the drug molecule penetrates through the cell membrane directly into the cytoplasm of a T-lymphocyte.

Once inside the cell, the substance finds its main target—a specific intracellular protein from the immunophilin family named cyclophilin. Firm binding occurs, resulting in the formation of an active complex.

It is this formed complex that takes on the task of blocking the activity of a key enzyme—calcineurin. Under normal conditions, this enzyme is a crucial link that triggers T-cell activation.

The final stage of the mechanism of action is that, due to the shutdown of calcineurin, the transition of a specific transcription factor (NFAT) into its active form is blocked. The consequence of this molecular block is the complete cessation of the activation of the gene responsible for the synthesis of interleukin-2 (IL-2). The outcome of this multi-step process is a potent inhibition of T-lymphocyte differentiation and subsequent proliferation.

Pharmacokinetic features

To achieve the required therapeutic effect in clinical practice, there are two main routes of administration of the drug into the patient's body:

• Oral route: the patient takes the drug by mouth.
• Parenteral route: the drug is administered intravenously, which is especially important in acute situations or the early postoperative period.

After the active substance enters the systemic circulation and distributes into tissues, the stage of its biotransformation begins. The drug's metabolism proceeds predominantly in the liver. The cytochrome P450 enzyme system plays a key role in the degradation and elimination of the molecule. To be precise, metabolism is carried out with the mandatory participation of the specific CYP3A4 isoenzyme. This pharmacokinetic fact requires extreme attention from the physician, as any other medications affecting this isoenzyme can unpredictably alter the concentration of the immunosuppressant in the blood.

Clinical application

The drug's ability to selectively turn off the T-cell link of immunity determined its main indications in modern clinical medicine. The drug is prescribed in situations where the patient's own immune system becomes a threat to their life or transplanted tissues.

1. Solid organ transplantation: This is the main sphere of application. The drug is vital for the prevention of graft rejection reactions. It is successfully used in the transplantation of such vital organs as the heart, lungs, liver, pancreas, and kidneys.
2. Oncohematology: The drug is included in treatment protocols during bone marrow transplantation to prevent aggressive immune reactions between donor cells and recipient tissues.
3. Systemic pathologies: In therapeutic and rheumatological practice, the agent is used for basic therapy of severe autoimmune diseases, when the immunity starts attacking the body's own healthy cells.

Safety profile and adverse effects

The use of such a potent immunosuppressant is associated with a number of serious risks. The drug is characterized by a narrow therapeutic index, and all its effects are strictly dose-dependent. That is why the gold standard of therapy is mandatory and regular monitoring of the substance concentration in the patient's blood plasma.

Main adverse effects:

• Nephrotoxicity: This is the most frequent and formidable complication. Toxic effects on the kidneys can lead to a decrease in their function. The risk of renal tissue damage increases manifold if the patient is simultaneously receiving antibacterial drugs from the aminoglycoside group or nonsteroidal anti-inflammatory drugs (NSAIDs).
• Hepatotoxicity: The drug is capable of exerting a direct damaging effect on liver cells.
• Secondary infections: Due to the expected suppression of immunity, patients become extremely vulnerable to various infectious agents, including severe viral infections.
• Allergic reactions: Manifestations of individual intolerance to the drug components are possible.

Rare adverse effects: Less commonly in clinical practice, yet still occurring, are complications such as neurotoxicity (nervous system damage), persistent arterial hypertension, hyperlipidemia (elevated blood fat levels), and hyperkalemia (dangerous increase in potassium levels). In addition, patients may encounter hirsutism—pathological excessive hair growth on the body.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• The role of the CYP3A4 isoenzyme in the metabolism of immunosuppressants
• Mechanisms of development of dose-dependent nephrotoxicity
• The significance of the NFAT factor in the T-lymphocyte activation cascade
• Features of therapeutic drug monitoring for agents with a narrow therapeutic index
• Prevention of secondary viral infections against the background of immunosuppression

Other topics in the section "Agents Regulating Immune Processes"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.